- Home
- RDNW vs PROF Comparison
RDNW vs PROF Comparison
Compare RDNW & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDNW | PROF |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | Canada |
| Employees | N/A | 162 |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.9M | 238.1M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | RDNW | PROF |
|---|---|---|
| Price | $6.32 | $6.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $6.50 | ★ $12.00 |
| AVG Volume (30 Days) | 58.5K | ★ 284.7K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | N/A | ★ 1.41 |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | $9.01 | $92.40 |
| Revenue Next Year | $6.53 | $64.10 |
| P/E Ratio | ★ N/A | $4.65 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $2.98 | $3.90 |
| 52 Week High | $7.19 | $8.95 |
Technical Indicators
Market Signals| Indicator | RDNW | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 50.14 | 53.95 |
| Support Level | $4.97 | $5.75 |
| Resistance Level | $7.12 | $7.08 |
| Average True Range (ATR) | 0.41 | 0.46 |
| MACD | 0.01 | 0.16 |
| Stochastic Oscillator | 50.32 | 77.54 |
Price Performance
Historical ComparisonAbout RDNW RideNow Group Inc.
RideNow Group Inc is a USA-based online retailer that allows consumers and dealers both to Buy-Sell-Trade-Finance pre-owned motorcycles in an efficient, fast, transparent, and engaging experience.
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.